Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronavirus Infections | 8 | 2020 | 190 | 1.840 |
Why?
|
| Pneumonia, Viral | 8 | 2020 | 202 | 1.830 |
Why?
|
| Hematoma | 3 | 2020 | 74 | 1.470 |
Why?
|
| Pandemics | 8 | 2020 | 628 | 1.150 |
Why?
|
| Neoplasms | 5 | 2020 | 1262 | 0.930 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2021 | 17 | 0.900 |
Why?
|
| Methemoglobinemia | 2 | 2020 | 5 | 0.870 |
Why?
|
| Oncologists | 2 | 2020 | 13 | 0.850 |
Why?
|
| Betacoronavirus | 7 | 2020 | 163 | 0.830 |
Why?
|
| Fibrinolytic Agents | 2 | 2020 | 165 | 0.780 |
Why?
|
| Thyroid Neoplasms | 2 | 2019 | 77 | 0.770 |
Why?
|
| Sarcoma, Myeloid | 1 | 2020 | 4 | 0.700 |
Why?
|
| Enoxaparin | 1 | 2020 | 16 | 0.690 |
Why?
|
| Gallbladder Neoplasms | 1 | 2020 | 17 | 0.690 |
Why?
|
| Shock, Hemorrhagic | 1 | 2020 | 20 | 0.690 |
Why?
|
| Hematology | 1 | 2020 | 11 | 0.690 |
Why?
|
| Bronchial Neoplasms | 1 | 2019 | 6 | 0.660 |
Why?
|
| Pyridones | 1 | 2020 | 35 | 0.660 |
Why?
|
| Lipoma | 1 | 2019 | 18 | 0.660 |
Why?
|
| Glucocorticoids | 1 | 2021 | 172 | 0.650 |
Why?
|
| Nutritional Status | 1 | 2020 | 120 | 0.650 |
Why?
|
| Pyrazoles | 1 | 2020 | 71 | 0.640 |
Why?
|
| Anticoagulants | 1 | 2020 | 489 | 0.510 |
Why?
|
| Laparoscopy | 1 | 2020 | 401 | 0.510 |
Why?
|
| Humans | 28 | 2021 | 60081 | 0.420 |
Why?
|
| Heart Failure | 1 | 2019 | 869 | 0.380 |
Why?
|
| Retroperitoneal Space | 2 | 2020 | 21 | 0.340 |
Why?
|
| ras Proteins | 1 | 2009 | 78 | 0.330 |
Why?
|
| Aged | 9 | 2020 | 13596 | 0.320 |
Why?
|
| ErbB Receptors | 1 | 2009 | 113 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 184 | 0.300 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 317 | 0.290 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 216 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 329 | 0.280 |
Why?
|
| Prognosis | 3 | 2019 | 1591 | 0.270 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 466 | 0.260 |
Why?
|
| Retrospective Studies | 5 | 2020 | 6147 | 0.260 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 646 | 0.260 |
Why?
|
| Male | 11 | 2020 | 27951 | 0.250 |
Why?
|
| Adult | 7 | 2020 | 15972 | 0.240 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 5200 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2002 | 170 | 0.210 |
Why?
|
| China | 2 | 2020 | 140 | 0.210 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 233 | 0.200 |
Why?
|
| Philadelphia Chromosome | 1 | 2002 | 3 | 0.200 |
Why?
|
| Infection Control | 2 | 2020 | 98 | 0.200 |
Why?
|
| Chromosome Inversion | 1 | 2002 | 18 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2002 | 26 | 0.200 |
Why?
|
| Mutation | 1 | 2009 | 2466 | 0.190 |
Why?
|
| Female | 9 | 2020 | 31226 | 0.180 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 460 | 0.180 |
Why?
|
| Middle Aged | 6 | 2020 | 16542 | 0.180 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 37 | 0.180 |
Why?
|
| Blood Donors | 1 | 2020 | 21 | 0.180 |
Why?
|
| Nutritionists | 1 | 2020 | 4 | 0.180 |
Why?
|
| Cyanosis | 1 | 2020 | 6 | 0.170 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2020 | 18 | 0.170 |
Why?
|
| Dapsone | 1 | 2020 | 9 | 0.170 |
Why?
|
| Thoracic Wall | 1 | 2020 | 17 | 0.170 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 27 | 0.170 |
Why?
|
| Blood Coagulation Factors | 1 | 2020 | 14 | 0.170 |
Why?
|
| Malnutrition | 1 | 2020 | 44 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 62 | 0.170 |
Why?
|
| Antimalarials | 1 | 2020 | 68 | 0.170 |
Why?
|
| Dyspnea | 1 | 2020 | 110 | 0.160 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2019 | 2 | 0.160 |
Why?
|
| Patients | 1 | 2020 | 103 | 0.160 |
Why?
|
| Iron | 1 | 2019 | 139 | 0.160 |
Why?
|
| Aspirin | 1 | 2020 | 172 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 142 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2019 | 215 | 0.150 |
Why?
|
| Income | 1 | 2019 | 162 | 0.150 |
Why?
|
| Survival Rate | 1 | 2020 | 793 | 0.140 |
Why?
|
| Pain | 1 | 2020 | 407 | 0.140 |
Why?
|
| Time Factors | 2 | 2021 | 3621 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 713 | 0.130 |
Why?
|
| Infant, Newborn | 1 | 2020 | 1315 | 0.130 |
Why?
|
| Algorithms | 1 | 2021 | 1006 | 0.120 |
Why?
|
| Biomarkers | 1 | 2019 | 1214 | 0.120 |
Why?
|
| Massachusetts | 1 | 2020 | 2119 | 0.110 |
Why?
|
| Dacarbazine | 2 | 2004 | 20 | 0.110 |
Why?
|
| Young Adult | 2 | 2020 | 4398 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2004 | 31 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2020 | 3133 | 0.100 |
Why?
|
| Immunization, Passive | 2 | 2020 | 99 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 56 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2021 | 5266 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 443 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1471 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2004 | 74 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 48 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2002 | 68 | 0.050 |
Why?
|
| Platelet Count | 1 | 2020 | 25 | 0.040 |
Why?
|
| Convalescence | 1 | 2020 | 17 | 0.040 |
Why?
|
| Blood Banks | 1 | 2020 | 8 | 0.040 |
Why?
|
| Primaquine | 1 | 2020 | 2 | 0.040 |
Why?
|
| New Zealand | 1 | 2020 | 34 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2020 | 9 | 0.040 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 7 | 0.040 |
Why?
|
| Donor Selection | 1 | 2020 | 16 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 15 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 31 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 37 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2020 | 35 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 45 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 134 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 183 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 134 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 558 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2020 | 151 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2019 | 32 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 68 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 215 | 0.040 |
Why?
|
| Cross Infection | 1 | 2020 | 154 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 2019 | 78 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 600 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 661 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 222 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2020 | 272 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2021 | 508 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2020 | 334 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 300 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 342 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 744 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 911 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 621 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 850 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1267 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 928 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1053 | 0.030 |
Why?
|
| United States | 2 | 2020 | 7622 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 651 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 856 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 1936 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 5090 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2004 | 20 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 42 | 0.010 |
Why?
|
| Fever | 1 | 2004 | 64 | 0.010 |
Why?
|
| Neutropenia | 1 | 2004 | 66 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2004 | 189 | 0.010 |
Why?
|
| Anemia | 1 | 2004 | 118 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2004 | 120 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 281 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 806 | 0.010 |
Why?
|